Skip to main content

CA 15-3 elevation in U.S. women without breast cancer.

Abstract

e13609
Background: Cancer antigen 15-3 (CA 15-3) is an epitope of Mucin 1 transmembrane glycoprotein, used to monitor response to therapy in metastatic breast cancer. Elevated CA 15-3 levels have been noted in other malignant and non-malignant conditions. This is the first population-based study examining CA 15-3 elevation in US women without breast cancer. Methods: Women without breast cancer were identified from the National Health and Nutrition Examination Survey 2001-2002 with CA 15-3 measurements via Meso Scale Discovery immunoassay. CA 15-3 levels were dichotomized per previously reported cutoffs of 20, 25, 30, and 40 U/ml, and also logarithmically transformed. Logistic and linear regression models were used to examine associations between CA 15-3 and demographic characteristics, gynecologic/reproductive history, inflammatory markers, non-malignant chronic conditions and non-breast malignancies. Results: Of 2432 women ages 20-85 (mean 48) years old, eighty (3.3%) had CA 15-3 ≥30 U/ml. Based on cutoff ≥30 U/ml, univariate logistic regression showed ages 40-59, uterine fibroids history, and salpingectomy history were associated with normal CA 15-3; Mexican American ethnicity and increasing C-reactive protein were associated with elevated CA 15-3. Multivariate logistic regression confirmed that only ages 40-49 (OR = 0.162, p = 0.0013) and uterine fibroids history (OR = 0.216, p = 0.0373) remained significantly associated. Similar results were found using other cutoffs. Univariate linear regression showed ages 40-59, salpingectomy history, and longer oral contraceptive pill (OCP) use correlated with lower CA 15-3; Black ethnicity, increasing ferritin, endometriosis history, and lung cancer history correlated with higher CA 15-3. Multivariate linear regression revealed significant associations: ages 50-59 (17.1% lower CA 15-3 vs ages < 40, p = 0.028); race other than White, Black, Hispanic, Mexican (32.0% lower CA 15-3 vs White, p = 0.039); longer OCP use (14.0% lower CA 15-3 for 2-5 yrs’ OCP use, p = 0.023; 21.0% lower for > 10 yrs’ OCP use, p = 0.006; vs OCP use < 2 yrs); endometriosis history (22.9% higher CA 15-3 vs no history, p = 0.051). CA 15-3 levels were not significantly associated with chronic liver conditions, coronary artery disease, or metabolic conditions (elevated BMI, diabetes, hyperlipidemia). Conclusions: Perimenopausal women, uterine fibroids history, and longer OCP use were associated with lower CA 15-3 levels, while non-White ethnicity and history of endometriosis were associated with higher CA 15-3. These findings help to elucidate interpretation of CA 15-3 in clinical practice.

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: e13609

History

Published in print: May 20, 2020
Published online: May 25, 2020

Permissions

Request permissions for this article.

Authors

Affiliations

Xiao Hu
Tufts Medical Center, Boston, MA;
Yu Cao
Tufts Medical Center, Boston, MA;
Tufts Medical Center, Boston, MA

Notes

Funding Information

None

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Xiao Hu, Yu Cao
Journal of Clinical Oncology 2020 38:15_suppl, e13609-e13609

View Options

View options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

Media

Figures

Other

Tables

Share

Share

Share article link

Share